Opportunity Information: Apply for PA 12 082
Apply for PA 12 082
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Biomechanisms of Peripheral Nerve Damage by Anti Cancer Therapy (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399 Cancer Control 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
- This funding opportunity was created on Jan 17, 2012 and posted on Jan 17, 2012.
- Applicants must submit their applications by May 7, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education For profit organizations other than small businesses Private institutions of higher education City or township governments Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) County governments Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R01) funding opportunity (PA 12-082) is a National Institutes of Health (NIH) grant program designed to push forward basic biological research on chemotherapy-induced peripheral neuropathy (CIPN). CIPN refers to damage to the peripheral nervous system caused by pharmacologic cancer treatments, and it can show up as painful neuropathy as well as disruptive sensory problems such as tingling (paresthesias), numbness, and loss of sensation (peripheral anesthesias). The FOA is centered on improving the field's understanding of how these cancer therapies injure peripheral nerves, with the longer-term intention of enabling more rational and effective ways to prevent CIPN or treat it once it starts.
A major motivation behind the announcement is that much of the broader peripheral neuropathy research landscape has historically been dominated by diabetic neuropathy and inherited neuropathies. NIH is explicitly trying to attract neuroscientists and related basic researchers who have built strong expertise in those areas and encourage them to redirect or adapt their tools, concepts, and experimental approaches to the neuropathies that arise from anti-cancer drugs. In other words, the FOA treats CIPN as a problem where the scientific community can benefit from "technology and knowledge transfer" from better-established neuropathy models, while recognizing that chemotherapy-related nerve damage may have distinct triggers, timelines, and biological signatures that still need to be mapped.
The scientific emphasis is on preclinical and mechanistic work. The announcement highlights a need for more data to clarify the biological mechanisms of neuronal injury in CIPN and to identify the molecular and cellular targets that are critical for both the initiation of neuropathy and its persistence over time. The focus is not limited to pain pathways; NIH is also inviting studies that address the broader spectrum of sensory dysfunction, including abnormal sensations and sensory loss that can seriously affect quality of life and can limit chemotherapy dosing. The underlying idea is that pain is only one piece of CIPN, and that a full mechanistic picture should account for the sensory abnormalities patients commonly report.
This opportunity uses the NIH R01 grant mechanism, supporting hypothesis-driven research projects that can deliver durable, foundational insights into disease biology. The stated end goal is to reach a molecular-level understanding of CIPN robust enough to point directly toward interventions, meaning preventatives and treatments that are grounded in a clear mechanistic rationale rather than trial-and-error symptom management. While the FOA is about basic biology, it is framed with translational intent: map the mechanisms well enough that target selection for therapies becomes straightforward and evidence-based.
From an administrative and eligibility standpoint, PA 12-082 was posted on January 17, 2012, with an original and final closing date of May 7, 2015, and it was archived June 7, 2015. It falls under discretionary grant funding, with activity categories tied to health and education, and it lists CFDA numbers 93.399 (Cancer Control) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders). Cost sharing is not required. Eligibility is broad and includes many U.S. and non-U.S. entity types: public and private institutions of higher education, nonprofits (including 501(c)(3) and other nonprofit structures), for-profit organizations (including small businesses), state and local governments, school districts, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, special district and regional organizations, and faith-based or community-based organizations. The FOA also states that foreign institutions and non-U.S. components of U.S. organizations may apply, and foreign components are allowed as defined by the NIH Grants Policy Statement.
Overall, the grant opportunity is best understood as an NIH effort to strengthen the basic science foundation of CIPN research by pulling in experienced neuropathy researchers, expanding attention beyond pain to include the full sensory phenotype, and building the mechanistic roadmap needed to design preventive and therapeutic strategies that can ultimately reduce the neurologic side effects of life-saving cancer treatments.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "The Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R01)" and is identified as PA 12-082.
Which agency is offering this grant?
This is a National Institutes of Health (NIH) funding opportunity.
What problem area does this FOA focus on?
The FOA focuses on chemotherapy-induced peripheral neuropathy (CIPN), meaning damage to the peripheral nervous system caused by pharmacologic cancer treatments.
What is chemotherapy-induced peripheral neuropathy (CIPN)?
CIPN refers to peripheral nerve damage caused by anti-cancer drug therapies. It can present as painful neuropathy and also as disruptive sensory problems.
What symptoms and sensory issues does the FOA highlight for CIPN?
The description highlights painful neuropathy as well as sensory dysfunction such as tingling (paresthesias), numbness, and loss of sensation (peripheral anesthesias). It also emphasizes that sensory abnormalities beyond pain can significantly affect quality of life and may limit chemotherapy dosing.
What is the main purpose of the research supported by this program?
The program is designed to push forward basic biological research that improves understanding of how cancer therapies injure peripheral nerves, with the longer-term goal of enabling more rational and effective prevention and treatment strategies for CIPN.
Is the emphasis clinical or preclinical?
The emphasis is on preclinical and mechanistic research, with a stated need for more data clarifying biological mechanisms of neuronal injury in CIPN.
What kind of scientific work is NIH trying to encourage under this FOA?
NIH is encouraging mechanistic studies that identify molecular and cellular targets important for both the initiation of neuropathy and its persistence over time, and that build a clearer biological map of neuronal injury caused by anti-cancer therapies.
Does the FOA focus only on pain mechanisms?
No. While pain is part of CIPN, the FOA explicitly invites studies that address the broader spectrum of sensory dysfunction, including abnormal sensations and sensory loss.
Why is NIH emphasizing "technology and knowledge transfer" from other neuropathy fields?
The FOA notes that peripheral neuropathy research has historically been dominated by diabetic neuropathy and inherited neuropathies. NIH aims to attract neuroscientists and other basic researchers with strong expertise in those areas and encourage them to adapt their tools, concepts, and experimental approaches to CIPN, while recognizing CIPN may have distinct triggers, timelines, and biological signatures.
What grant mechanism does this opportunity use?
This opportunity uses the NIH R01 grant mechanism.
What type of projects is an R01 meant to support in this context?
In this FOA, the R01 mechanism supports hypothesis-driven research projects intended to deliver durable, foundational insights into the biology of chemotherapy-induced peripheral neuropathy.
What is the longer-term goal of the mechanistic research described here?
The longer-term goal is to achieve a molecular-level understanding of CIPN robust enough to point directly toward interventions, including preventatives and treatments, based on clear mechanistic rationale rather than trial-and-error symptom management.
Is this FOA purely basic science, or is there a translational intent?
It is framed as basic biology with translational intent: mapping mechanisms thoroughly so that selecting targets for therapies becomes straightforward and evidence-based.
When was PA 12-082 posted?
PA 12-082 was posted on January 17, 2012.
What were the original and final closing dates?
The FOA lists an original and final closing date of May 7, 2015.
Is the opportunity still open?
No. The FOA was archived on June 7, 2015, and its final closing date was May 7, 2015.
What kind of funding classification is mentioned?
It is described as discretionary grant funding, with activity categories tied to health and education.
Which CFDA numbers are associated with this opportunity?
The FOA lists CFDA 93.399 (Cancer Control) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders).
Is cost sharing required?
No. Cost sharing is not required.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofits (including 501(c)(3) and other nonprofit structures); for-profit organizations (including small businesses); state and local governments; school districts; tribal governments and tribal organizations; public housing authorities/Indian housing authorities; special district and regional organizations; and faith-based or community-based organizations.
Can non-U.S. organizations apply?
Yes. The FOA states that foreign institutions and non-U.S. components of U.S. organizations may apply, and that foreign components are allowed as defined by the NIH Grants Policy Statement.
What is the overall rationale for this NIH initiative?
Overall, the opportunity reflects an NIH effort to strengthen the basic science foundation of CIPN research by pulling in experienced neuropathy researchers, expanding attention beyond pain to include the full sensory phenotype, and building a mechanistic roadmap needed to support prevention and treatment strategies that reduce neurologic side effects of cancer therapies.
Browse more opportunities from the same category: Education Health
Next opportunity: ROSES 2011 HyspIRI Preparatory Airborne Activities and Associated Science
Previous opportunity: Newborn Screening Technical Assistance and Data Repository Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 082
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 082) also looked into and applied for these:
| Funding Opportunity |
|---|
| Leadership Group for a Clinical Research Network on Integrated Strategies to Prevent HIV Infection (UM1) Apply for RFA AI 12 011 Funding Number: RFA AI 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cutting Edge Basic Research Awards (CEBRA) (R21) Apply for PAR 12 086 Funding Number: PAR 12 086 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Basic Cancer Research in Cancer Health Disparities (U01) Apply for PAR 12 095 Funding Number: PAR 12 095 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21) Apply for PAR 12 094 Funding Number: PAR 12 094 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21) Apply for PAR 12 096 Funding Number: PAR 12 096 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phased Services Research Studies of Drug Use Prevention, Addiction Treatment, and HIV in an Era of Health Care Reform (R21/R33) Apply for RFA DA 13 001 Funding Number: RFA DA 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Centers of Excellence in Symptom Science (P30) Apply for RFA NR 12 006 Funding Number: RFA NR 12 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $480,000 |
| Centers of Excellence in Symptom Science Building Research Teams for the Future (P20) Apply for RFA NR 12 009 Funding Number: RFA NR 12 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| NLM Information Resource Grants to Reduce Health Disparities (G08) Apply for RFA LM 12 001 Funding Number: RFA LM 12 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The NCI Transition Career Development Award (K22) Apply for PAR 12 121 Funding Number: PAR 12 121 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01) Apply for PA 12 127 Funding Number: PA 12 127 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21) Apply for PA 12 128 Funding Number: PA 12 128 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03) Apply for PA 12 129 Funding Number: PA 12 129 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34) Apply for PA 12 130 Funding Number: PA 12 130 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Research to Assist Informal Caregivers in Assessing and Managing Symptoms in Individuals with Alzheimers Disease (R01) Apply for RFA NR 12 011 Funding Number: RFA NR 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Translational Research at the Aging/Cancer Interface (TRACI) (R21) Apply for PA 12 135 Funding Number: PA 12 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research at the Aging/Cancer Interface (TRACI) (R01) Apply for PA 12 136 Funding Number: PA 12 136 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Early Detection and Prevention of Mild Cognitive Impairment (R01) Apply for RFA NR 12 010 Funding Number: RFA NR 12 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) Apply for PAS 12 122 Funding Number: PAS 12 122 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,000,000 |
| Technology Based Interventions to Promote Engagement in Care and Treatment Adherence for Substance Abusing Populations with HIV (R01) Apply for PA 12 117 Funding Number: PA 12 117 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 082", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.